Bayer Diagnostics launches immunoassay system
8 September 2006
Tarrytown, N.Y., USA. Bayer HealthCare, Diagnostics
Division, a member of the Bayer Group (NYSE: BAY - News), has announced the
worldwide availability of its ADVIA Centaur XP Immunoassay System.
ADVIA Centaur XP system is a fully-automated, high-throughput immunoassay
system enabling hospitals and reference laboratories to perform up to 240
tests per hour to keep pace with peak load times. It provides a portfolio of
65 disease state tests, and over 226 specific allergens and mixes, providing
consolidation while balancing a laboratory's need for improved patient care.
The new system uses the same proven assay methodologies and reagent packs as
ADVIA Centaur system and ADVIA Centaur CP system. The comprehensive menu of
disease state assay groups — including cardiovascular, oncology, fertility,
and infectious disease testing capabilities — currently available on the
ADVIA Centaur system and ADVIA Centaur CP system are also available on ADVIA
Centaur XP system.
"Our aim is to better serve our customers by offering more analytical
platforms, more assays and improved connectivity and integration," said Tony
Bihl, President of Bayer Diagnostics. "The addition of ADVIA Centaur XP
system to Bayer's portfolio provides additional ease-of-use, automation, and
expanded capabilities for significant impact on productivity in a
laboratory, while improving patient care."